Baby Brent’s Bill
- Sponsor
- Rep. Pappas, Chris [D-NH-1]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jul 27, 2026
Bottom line
The bill mandates an FTC investigation and subsequent rulemaking to ensure transparent and non-deceptive advertising of preterm infant formula, aiming to protect vulnerable infants and their families.
What it actually does
This bill directs the Federal Trade Commission (FTC) to investigate potentially unfair or deceptive advertising and marketing practices for preterm infant formula, specifically considering the exclusion of health risks and differences between human milk-based and bovine-based fortifiers. Following the investigation, the FTC must issue regulations to prohibit such practices and enforce them under existing Federal Trade Commission Act powers. The bill also includes a Sense of Congress emphasizing the importance of informed parental decisions and legal recourse for harm to preterm infants.
Proponents argue
Supporters argue that parents of preterm infants need complete and accurate information to make critical health decisions, especially given the documented risks like necrotizing enterocolitis (NEC) and the perceived safety differences between human milk-based and bovine-based fortifiers. They contend that manufacturers should not be allowed to use deceptive marketing to obscure potential health risks or limit families' ability to seek compensation for harm, thereby safeguarding the health and legal rights of preterm infants.
Opponents contend
Critics might argue that the bill introduces unnecessary regulatory burdens on a highly specialized industry already subject to FDA oversight, potentially increasing costs for manufacturers which could be passed on to consumers or limit product availability. They may also contend that existing consumer protection laws are sufficient and that the bill's directives could lead to subjective enforcement, stifling legitimate communication about product benefits to healthcare professionals and parents.
The bill is short and clearly written, allowing for a quick and comprehensive understanding of its provisions.
Section 3(a)
FTC Investigation and Report on Preterm Infant Formula Advertising
This provision mandates the Federal Trade Commission (FTC) to conduct an investigation into the advertising and marketing practices of preterm infant formula. The investigation must identify any potentially unfair or deceptive acts, specifically looking at whether marketing materials fail to disclose potential health risks or adequately explain the differences, benefits, and drawbacks between human milk-based and bovine-based fortifiers. The FTC is required to submit a report to Congress within one year, including any recommendations for legislative or administrative action.
Supporters argue
Supporters argue that an FTC investigation is crucial to uncover and document any deceptive practices in the marketing of preterm infant formula, ensuring that parents receive accurate and complete information. This proactive step is seen as essential for protecting vulnerable preterm infants from potential harm linked to inadequate disclosure of risks or product differences.
Critics contend
Critics might contend that such an investigation could be redundant, as the FDA already regulates infant formula, and existing consumer protection laws are sufficient. They might also argue it could create an adversarial environment that discourages innovation or necessary communication within the specialized medical nutrition sector.
Tradeoffs
The provision balances the need for consumer protection and transparency for a vulnerable population against potential regulatory burdens on manufacturers and the possibility of overlapping agency jurisdiction.
Section 3(b)
FTC Regulations to Prohibit Deceptive Practices
This provision directs the Federal Trade Commission (FTC) to issue new regulations within 18 months after submitting its investigation report to Congress. These regulations will specifically prohibit any manufacturer or importer of preterm infant formula from engaging in unfair or deceptive advertising or marketing practices. The regulations must address the omission of potential health risks and the failure to disclose differences, benefits, and drawbacks between human breast milk/human milk-based fortifiers and bovine-based fortifiers.
Section 3(c)
Enforcement of Regulations
This provision specifies that any violation of the new regulations promulgated by the FTC regarding preterm infant formula advertising will be treated as a violation of a rule defining an unfair or deceptive act or practice under the Federal Trade Commission Act. This means the FTC will have its full range of enforcement powers, including investigations, cease and desist orders, and civil penalties, to address non-compliance by manufacturers or importers. Those who violate the regulations will be subject to the same penalties and entitled to the same privileges and immunities as under the existing FTC Act.
States that no manufacturer of preterm infant formula or related products should be permitted to limit, evade, or otherwise diminish the ability of families to pursue legal recourse when their preterm infants experience harm.
Section 2, Paragraph (7)
Why it matters:While 'Sense of Congress' statements are often used to express legislative intent without creating new law, this particular statement sets a strong moral and policy precedent regarding manufacturer liability, which could influence judicial interpretations or future legislative efforts. It's 'buried' in the sense that it's not an operative provision creating new law, but it clearly signals legislative intent on a contentious issue.
Case for: Proponents argue that this statement reinforces the fundamental right of families to seek justice and compensation if their preterm infants are harmed due to product-related factors, especially if marketing was deceptive. It underscores the importance of corporate accountability and consumer protection for a highly vulnerable population.
Case against: Manufacturers and their advocates might argue that such a statement, even if non-binding, could be used to influence public opinion or judicial proceedings, potentially prejudicing legal outcomes or increasing liability risks beyond what is currently established in law. They might also argue it could discourage product development if liability risks are perceived as too high.
Estimated impact: This provision does not directly create new legal rights or liabilities but expresses a strong legislative intent that could influence future legal interpretations or legislative actions regarding manufacturer liability for preterm infant formula.
Defines 'preterm infant formula' as any infant formula that is exempt under section 412(h)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 350a(h)(1)) and is intended to be administered to a preterm infant.
Section 3(d)(3)
Why it matters:Referencing existing law for definitions is standard legislative practice for precision and to avoid redundancy. However, it means a reader must consult external statutes to fully grasp which specific formulas are covered by this bill.
Case for: Proponents argue that precisely defining 'preterm infant formula' by referencing existing federal law ensures clarity and consistency with established regulatory frameworks for infant formula, preventing ambiguity in the application of the bill's provisions.
Case against: No specific opposition is typically raised against clear and precise definitions, as they are essential for effective legislation. However, if the referenced section of the Food, Drug, and Cosmetic Act were controversial, the definition itself could become a point of contention.
Estimated impact: This definition precisely delineates the scope of products subject to the FTC's investigation and regulation, directly impacting manufacturers of specialized infant formulas for preterm infants.